IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
This study has been completed.
Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Identifier:
NCT00445744
First received: March 7, 2007
Last updated: April 3, 2014
Last verified: April 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This trial is studying the side effects and how well giving cyclophosphamide and busulfan followed by donor stem cell transplant works in treating patients with myelofibrosis, acute myeloid leukemia, or myelodysplastic syndrome. Giving chemotherapy, such as cyclophosphamide and busulfan, before a donor stem cell transplant helps stops the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and methotrexate after the transplant may stop this from happening
| Condition | Intervention |
|---|---|
| Adult Acute Myeloid Leukemia in Remission Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Childhood Acute Myeloid Leukemia in Remission Childhood Myelodysplastic Syndromes de Novo Myelodysplastic Syndromes Essential Thrombocythemia Myelodysplastic Syndrome With Isolated Del(5q) Polycythemia Vera Previously Treated Myelodysplastic Syndromes Primary Myelofibrosis Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndromes Secondary Myelofibrosis Untreated Adult Acute Myeloid Leukemia Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies | Drug: cyclophosphamide Drug: busulfan Drug: tacrolimus Drug: methotrexate Genetic: cytogenetic analysis Other: flow cytometry Other: pharmacological study Other: pharmacogenomic studies Procedure: peripheral blood stem cell transplantation Procedure: allogeneic hematopoietic stem cell transplantation |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Cyclophosphamide Followed by Intravenous Busulfan as Conditioning for Hematopoietic Cell Transplantation in Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome. |
Resource links provided by NLM:
Genetics Home Reference related topics:
core binding factor acute myeloid leukemia
cytogenetically normal acute myeloid leukemia
familial acute myeloid leukemia with mutated CEBPA
primary myelofibrosis
Genetic and Rare Diseases Information Center resources:
Myeloid Leukemia
Acute Myeloid Leukemia
Acute Non Lymphoblastic Leukemia
Myelodysplastic Syndromes
Myelofibrosis
Essential Thrombocythemia
Polycythemia Vera
Chronic Myeloproliferative Disorders
U.S. FDA Resources
Further study details as provided by Fred Hutchinson Cancer Research Center:
Primary Outcome Measures:
- Effectiveness of cyclophosphamide/busulfan regimen in reducing regimen-related toxicity [ Time Frame: Up to day +20 ]Diagnoses will be made according to the established criteria initially proposed in 1984 by McDonald et al.
- Non-relapse mortality (NRM) (patients with AML/MDS) [ Time Frame: At day +200 ]
| Enrollment: | 52 |
| Study Start Date: | December 2006 |
| Study Completion Date: | June 2013 |
| Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Treatment (cyclophosphamide, busulfan, transplant)
CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0. POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11. |
Drug: cyclophosphamide
Given IV
Other Names:
Drug: busulfan
Given IV
Other Names:
Drug: tacrolimus
Given IV or PO
Other Names:
Drug: methotrexate
Given IV
Other Names:
Genetic: cytogenetic analysis
Correlative studies
Other: flow cytometry
Correlative studies
Other: pharmacological study
Correlative studies
Other Name: pharmacological studies
Other: pharmacogenomic studies
Correlative studies
Other Name: Pharmacogenomic Study
Procedure: peripheral blood stem cell transplantation
Undergo PBPC transplantation
Other Names:
Procedure: allogeneic hematopoietic stem cell transplantation
Undergo allogeneic transplantation
|
Detailed Description:
PRIMARY OBJECTIVES:
I. To estimate the incidence of hepatotoxicity with a conditioning regimen of CY (cyclophosphamide)/tBU (busulfan) in patients receiving hematopoietic cell transplant (HCT).
SECONDARY OBJECTIVES:
I. To determine overall and non-relapse mortality at day +200 after HCT.
II. To determine the peak bilirubin levels through day +20 after HCT.
III. To determine the incidence of pulmonary toxicity in the form of idiopathic pulmonary syndrome (IPS).
IV. To determine the rate of graft failure.
V. To determine the time to engraftment.
VI. To determine the rate of relapse.
VII. To determine the incidence and severity of graft-versus-host disease (GVHD).
VIII. To evaluate the pharmacokinetics/dynamics of BU and CY.
X. To evaluate the pharmacogenomics of response, toxicity and pharmacokinetics of CY/tBU.
OUTLINE:
CONDITIONING REGIMEN: Patients receive cyclophosphamide intravenously (IV) on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.
TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.
POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or orally (PO) twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11.
After completion of study treatment, patients are followed periodically.
Eligibility| Ages Eligible for Study: | up to 65 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Idiopathic myelofibrosis (CIMF)
- Myelofibrosis developing with polycythemia vera or essential thrombocythemia
- Acute myeloid leukemia with or without antecedent hematologic disorder, at any disease stage (complete remission, minimal residual disease, or relapsed leukemia)
- Myelodysplastic syndrome of any World Health Organization (WHO) or French-American-British (FAB) category, at any disease stage
- Less than 61 years of age if transplanted from an unrelated donor, or less than 66 years of age if transplanted from a related donor
- Receiving unmanipulated peripheral blood stem cells from an human leukocyte antigen (HLA)-identical or 1-allele-mismatched related or unrelated donor, or receiving G-CSF-stimulated bone marrow if co-enrolled on Fred Hutchinson Cancer Research Center (FHCRC) protocol 2250
- With a Karnofsky Performance score of > 70% at the time of pre-transplant evaluation
- Able to give informed consent (if >= 18 years of age), or with a legal guardian capable of giving consent (if < 18 years of age)
- DONOR: HLA-identical or 1-allele-mismatched related or unrelated donors (by high resolution typing)
- DONOR: Undergoing peripheral blood stem cell harvest or G-CSF-stimulated bone marrow harvest (bone marrow permitted only as part of FHCRC protocol 2250)
- DONOR: In good general health, with a Karnofsky performance score of > 80%
- DONOR: Able to give informed consent (if >= 18 years of age), or with a legal guardian able to give informed consent (if < 18 years of age and donating for a related transplant)
Exclusion Criteria:
- Without an HLA-identical or 1-allele-mismatched related or unrelated donor
- With human immunodeficiency virus (HIV) positivity or active infectious hepatitis
- Receiving a medication known to strongly inhibit enzymes in the CYP450 pathway, and which, in the judgment of the consenting provider, cannot be safely discontinued for the duration of conditioning
- Whose life expectancy is severely limited by diseases other than the hematologic disorder for which they are undergoing HCT (HCT-comorbidity index [CI] > 3)
- Women who are pregnant or lactating
- With known hypersensitivity to BU or CY
- With hepatic dysfunction as evidenced by total bilirubin or AST > 2x the upper limit of normal, or evidence of synthetic dysfunction or cirrhosis
- With impaired renal function, as evidenced by creatinine clearance < 50% of expected, creatinine > 2x the upper limit of normal, or dialysis dependence
- With impaired pulmonary function, as evidenced by pO2 < 70 mm Hg and diffusing capacity of carbon monoxide (DLCO) < 70% predicted or by pO2 < 80 mm Hg and DLCO < 60%, or receiving continuous supplementary oxygen
- With impaired cardiac function, as evidenced by ejection fraction < 35% or active coronary artery disease
- Unable to give informed consent
- DONOR: Deemed unable to undergo stem cell collection, for any reason
- DONOR: HIV-positive, or hepatitis B or C antigen-positive
- DONOR: Women with a positive pregnancy test
- DONOR: Unable to give informed consent (if >= 18 years of age), or without a legal guardian able to give informed consent (if <18 years of age)
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00445744
Please refer to this study by its ClinicalTrials.gov identifier: NCT00445744
Locations
| United States, Washington | |
| Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | |
| Seattle, Washington, United States, 98109 | |
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Andrew Rezvani | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium |
More Information
| Responsible Party: | Fred Hutchinson Cancer Research Center |
| ClinicalTrials.gov Identifier: | NCT00445744 History of Changes |
| Other Study ID Numbers: |
2130.00 NCI-2010-00270 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) P01HL036444 ( US NIH Grant/Contract Award Number ) |
| Study First Received: | March 7, 2007 |
| Last Updated: | April 3, 2014 |
Additional relevant MeSH terms:
|
Syndrome Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Myelodysplastic Syndromes Preleukemia Neoplasm Metastasis Primary Myelofibrosis Thrombocythemia, Essential Polycythemia Polycythemia Vera Thrombocytosis Disease Pathologic Processes Neoplasms by Histologic Type |
Neoplasms Bone Marrow Diseases Hematologic Diseases Precancerous Conditions Neoplastic Processes Myeloproliferative Disorders Blood Coagulation Disorders Blood Platelet Disorders Hemorrhagic Disorders Methotrexate Tacrolimus Cyclophosphamide Busulfan Abortifacient Agents, Nonsteroidal Abortifacient Agents |
ClinicalTrials.gov processed this record on June 23, 2017